All In Biotech

Drug Trial Radar · NCT02142153

F901318 Single Ascending Dose Study in Healthy Male Volunteers

F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Sep 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Aug 2014

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
F2G LtdIndustry
Sponsor type
Industry
Collaborators
Simbec Research
First posted
May 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.

Conditions

  • Invasive Aspergillosis

Interventions

  • F901318Drug

    Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities. Pharmacokinetic profile

  • PlaceboDrug

    Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Adverse EventsTime frame: Single dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Simbec Research

    Merthyr Tydfil, Mid Glamorgan, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.